Multicentre, Short-term Therapeutic Trial of Disodium Cromoglycate, With and Without Prednisone, in Adults with AsthmaBMJ 1972; 4 doi: http://dx.doi.org/10.1136/bmj.4.5840.576 (Published 09 December 1972) Cite this as: BMJ 1972;4:576
- T. Gebbie,
- E. A. Harris,
- T. V. O'Donnell,
- G. F. S. Spears
A total of 117 asthmatic patients were studied in a double-blind, cross-over trial with half-periods of three weeks in which disodium cromoglycate (D.S.C.G.) was compared with an inactive preparation. D.S.C.G. improved spirometric measurements, at a very high level of statistical significance, more than did placebo. The mean advantage of D.S.C.G. was less than 10% after three weeks. Symptomatic improvement by D.S.C.G. was small though significant; it was not correlated with spirometric improvement. A history of chronic cough was the only clinical characteristic associated with a better-than-average spirometric response to D.S.C.G.
↵* Report on a trial co-ordinated by the Clinical Trials Committee of the Medical Research Council of New Zealand.